Ripretinib Alternatives Compared
| Ripretinib | Gleevec (imatinib) | Imatinib |
|
|---|
| Ripretinib | Gleevec (imatinib) | Imatinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Gastrointestinal Stromal Tumor. Ripretinib may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome... View more |
Related suggestions Gastrointestinal Stromal Tumor
|
|||||||||||||||
| More about Ripretinib | More about Gleevec (imatinib) | More about Imatinib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Ripretinib has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 5% reported a negative effect. |
Imatinib has an average rating of 8.8 out of 10 from a total of 47 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ripretinib side effects |
View all Gleevec side effects |
View all Imatinib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Imatinib prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Qinlock | Other imatinib brands include: Imkeldi | Gleevec, Imkeldi | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
17.8 hours |
40 hours |
40 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 341 drugs are known to interact with Ripretinib:
|
A total of 769 drugs are known to interact with Gleevec:
|
A total of 769 drugs are known to interact with Imatinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 15, 2020 |
May 10, 2001 |
April 18, 2003 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.